EUCTR2006-002055-32-DE进行中（未招募）不适用
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - NA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •The study population is men with LUTS and BPE/bladder outlet obstruction (BOO):
- •1. Males aged 18 years and above.
- •2. Symptoms of LUTS for =6 months prior to baseline.
- •3. IPSS score of 8 - 19 at baseline.
- •4. Maximum urine flow =5 mL/sec and =12 mL/sec on 125 mL voided volume.
- •5. Post-void residual volume <150 mL.
- •6. Written informed consent.
- •7. If male subject and partner are of child bearing potential, agree to use a secure form of contraception (e.g. oral or injectable contraceptive, condom).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Uncontrolled hypertension >160/95 mmHg (after sitting for 5 minutes).
- •2. Concomitant or recent medication for BPE: 5a-reductase inhibitors within 6 months prior to baseline or alpha-adrenergic receptor blockers within 3 months prior to baseline.
- •3. Use of anticholinergics in the two weeks prior to baseline (four weeks for solifenacen).
- •4. Previous surgery for BOO.
- •5. Acute urinary retention in the 12 months prior to baseline.
- •6. Urinary tract infection within 6 weeks prior to baseline.
- •7. History of significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness.
- •8. Unstable cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart failure.
- •9. Clinically significant central nervous system disease including: Parkinson’s disease, multiple sclerosis, transient ischemic attack, stroke, seizure disorder, depression, or behavioural disturbances.
- •10. History of peripheral vascular or cerebrovascular disease.
- •11. History of narrow angle glaucoma or increased ocular pressure.
- •12. Clinically significant gastrointestinal disorder (e.g., gastroparesis, constipation, diarrhoea, colitis, gastrointestinal tract obstruction, hiatal hernia with reflux oesophagitis, cholestasis).
- •13. History of clinically significant liver disease, e.g., hepatitis B
- •14. Prohibited medications taken within two weeks prior to baseline.
- •15. Concomitant use of any agent that has a significant interaction with CYP3A4 or P glycoprotein (Pgp).
- •16. Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, complete blood count [CBC], chemistry panel).
- •17. Participation in an investigational drug or device study within 30 days prior to screening.
- •18. Concomitant urological disorders: bladder neck stenosis, urethral stricture, bladder stones, bladder diverticulum, recurrent urinary tract infections, neurogenic bladder.
- •19. Diagnosed or suspected prostate cancer.
- •20. Known hypersensitivity to anti-cholinergic agents.
- •21. Unwillingness or inability to comply with the study protocol for any other reason.
- •22. Concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study; or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. This would include, but is not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease.
- •23. Any clinically significant abnormality on 12-lead ECG.
研究者
相似试验
进行中（未招募）
1 期
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - PSD506-OAB-004benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS)MedDRA version: 8.1 Level: LLT Classification code 10055026 Term: Prostatic obstructionEUCTR2006-002055-32-IEPlethora Solutions Limited80
进行中（未招募）
不适用
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - PSD506-OAB-004benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS)MedDRA version: 8.1Level: LLTClassification code 10055026Term: Prostatic obstructionEUCTR2006-002055-32-GBPlethora Solutions Limited80
已完成
不适用
A double-blind, placebo-controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction and lower urinary tract symptomsMen with LUTS and BPE/BOOUrological and Genital DiseasesBenign prostatic obstruction and lower urinary tract symptomsISRCTN71613863Plethora Solutions Limited (UK)88
进行中（未招募）
1 期
The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machineVon Willebrand Disease (VWD)MedDRA version: 20.0Level: PTClassification code 10069495Term: Acquired Von Willebrand's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-003036-37-ATTirol Kliniken GmbH68
进行中（未招募）
1 期
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorderBinge eating disorder (BED)MedDRA version: 24.0Level: PTClassification code 10004716Term: Binge eatingSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-000472-11-FRBIOPROJET PHARMA66